Contracts › HT942524C0076
HT942524C0076: Developing In-007 As a Widely Deployable Inhaled Treatment Against Pathogens Utilizing Human ACE2 for Viral Attachment and Entry
Awarded to Inhalon Biopharma, Inc. by Defense Health Agency.
$2.2Mobligated
$2.2Mpotential value
22 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HT942524C0076 |
|---|---|
| Awardee | Inhalon Biopharma, Inc. |
| Awarding agency | Defense Health Agency |
| Awarding office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NC |
| Offers received | 47 |
| Period of performance | 23 September 2024 to 22 December 2026 |
| Potential end | 22 December 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record